Salvage radiotherapy of prostate cancer recurrences after radical prostatectomy
S. I. Tkachev,
P. V. Bulychkin,
V. B. Matveev,
A. V. Nazarenko,
V. O. Panov,
F. A. Kossov,
G. I. Akhverdieva https://doi.org/10.17650/1726-9776-2018-14-1-100-106
Abstract
Objective: to evaluate the effectiveness of salvage radiotherapy in patients with recurrent prostate cancer after radical prostatectomy.
Materials and methods. In the period from March 2009 to January 2015, 92 patients with prostate cancer and biochemical recurrences after radical prostatectomy underwent salvage radiotherapy with classic fractionation and hypofractionation of the radiation dose.
Results and conclusion. Median follow-up duration was 40 months (12–78 months). Overall survival was 100 %. Local control was 100 %. One (1), 2, and 3-year disease-free survival in the whole patient group was 96, 91, and 86 %; in the hypofractionation group it was 98, 95, and 89 %; in the classical fractionation group it was 95, 87, and 84 %, respectively. We have determined that the period of doubling of prostate-specific antigen level of ≤6 months (p = 0.035) after surgical treatment and prostate-specific antigen level >0.5 ng/ml (p = 0.037) at the time of salvage radiotherapy are significantly associated with worse prognosis for treatment effectiveness. There weren’t any differences in late toxicity between the 2 patient groups.
About the Authors
S. I. Tkachev
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Competing Interests: Отсутствие конфликта интересов
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
Competing Interests: Отсутствие конфликта интересов
P. V. Bulychkin
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Competing Interests: Отсутствие конфликта интересов
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
Competing Interests: Отсутствие конфликта интересов
V. B. Matveev
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Competing Interests: Отсутствие конфликта интересов
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
Competing Interests: Отсутствие конфликта интересов
A. V. Nazarenko
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Competing Interests: Отсутствие конфликта интересов
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
Competing Interests: Отсутствие конфликта интересов
V. O. Panov
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Competing Interests: Отсутствие конфликта интересов
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
Competing Interests: Отсутствие конфликта интересов
F. A. Kossov
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Competing Interests: Отсутствие конфликта интересов
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
Competing Interests: Отсутствие конфликта интересов
G. I. Akhverdieva
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Competing Interests: Отсутствие конфликта интересов
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
Competing Interests: Отсутствие конфликта интересов
References
1. Malignant tumors in Russia in 2015 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMIRTS” Minzdrava Rossii, 2017. 250 p. (In Russ.).
2. Makarov D.V., Trock B.J., Humphreys E.B. et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate – specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007;69(6):1095–101. DOI: 10.1016/j.urology.2007.03.042. PMID: 17572194.
3. Schild S.E., Wong W.W., Grado G.L. et al. Radiotherapy for isolated increases in serum prostate-specific antigen levels after radical prostatectomy. Mayo Clin Proc 1994;69(7):613–9. PMID: 7516988.
4. Siegmann A., Bottke D., Faehndrich J. et al. Salvage radiotherapy after prostatectomy – what is the best time to treat? Radiother Oncol 2012;103(2):239–43. DOI: 10.1016/j.radonc.2011.10.024. PMID:22119375.
5. Stephenson A.J., Scardino P.T., Kattan M.W. et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007;25(15):2035–41. PMID: 17513807. DOI: 10.1200/JCO.2006.08.9607.
6. Cox J.D., Stets J., Pajak T.F. et al. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31(5):1341–6. DOI: 10.1016/0360-3016(95)00060-C. PMID: 7713792.
7. Pound C.R., Partin A.W., Eisenberger M.A. et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281(17):1591–7. PMID: 10235151.
8. Palermo G., Torato A., Sacco E. et al. High intensity focused ultrasound as first line salvage therapy in prostate cancer local relapse after radical prostatectomy: 4-year follow-up outcomes. Minerva Urol Nefrol 2017;69(1):93–100. DOI: 10.23736/S0393-2249.16.02696-5. PMID: 28009150.
9. Gomez-Veiga F., Mariño A., Alvarez L. et al. Brachytherapy for the treatment of recurrent prostate cancer after radiotherapy or radical prostatectomy. BJU Int 2012;109:17–21. DOI: 10.1111/j.1464-410X.2011.10826.x. PMID: 22239225.
10. Grishina Yu.A., Khmelevskiy E.V. Radiotherapy for local recurrences of prostate cancer after radical prostatectomy. Voprosy onkologii = Problems in Oncology 2015;(1):7–13. (In Russ.).
Review
For citations:
Tkachev S.I., Bulychkin P.V., Matveev V.B., Nazarenko A.V., Panov V.O., Kossov F.A., Akhverdieva G.I. Salvage radiotherapy of prostate cancer recurrences after radical prostatectomy. Cancer Urology. 2018;14(1):100-106. (In Russ.) https://doi.org/10.17650/1726-9776-2018-14-1-100-106
Views:
4966
Email this article 